By selecting the Yes option, Leave Amgen.co.uk option, you understand that you are leaving the corporate page of Amgen UK and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen upholds the highest standards of transparency and accountability in the pharmaceutical industry. We are fully compliant with the disclosure requirements of the ABPI Code of Practice for the Pharmaceutical Industry.
At Amgen, we strive to improve patient care through our partnerships with the NHS and other organisations. We adhere to the highest ethical standards and follow the principles of collaborative working.
Collaborative working refers to the initiatives that we undertake with other organisations to improve patient care, benefit patients, or support the NHS while maintaining patient care. A specific type of collaborative working is joint working, which focuses on patient outcomes and always benefits patients.
Below you can find more information about our collaborative working and joint working projects and transfers of value.
Amgen partners with the NHS and other organisations for the benefit of patients and in a way that is true to the Industry Codes of Practice and Amgen’s policy. Amgen is committed to making public the scope of its partnerships in the UK and Ireland in order to increase transparency. This includes stating the transfers of value associated with all collaborative working projects each year.
| Academic Health Science Network for the North East and North Cumbria (AHSN-NENC) | £ 9,590 |
| Barts Health NHS Trust on behalf of North Thames Genomics Laboratory Hub | £ 40,784.46 |
| Cardiff & Vale University Health Board | £77,500 |
| Hywel Dda University Health Board | £311,374 |
| The Innovation Agency – Academic Health Science Network (AHSN) for the North West Coast | £3,836 |
| Manchester University NHS Foundation Trust on behalf of North West GLH | £3,600 |
| Royal Devon & Exeter NHS Foundation Trust on behalf of NHS South West Genomic Medicine Service Alliance | £6,432 |
| Swansea University | £289,580.83 |
| University Hospitals Birmingham NHS Foundation Trust | £31,804 |
Amgen partners with the NHS and other organisations for the benefit of patients and in a way that is true to the Industry Codes of Practice and Amgen’s policy. Amgen is committed to making public the scope of its partnerships in the UK and Ireland in order to increase transparency. This includes stating the transfers of value associated with all collaborative working projects each year.
| Academic Health Science Network for the North East and North Cumbria (AHSN-NENC) | £ 11,509 |
| Barts Health NHS Trust on behalf of North Thames Genomics Laboratory Hub | £ 10,897 |
| Buckinghamshire Clinical Commissioning Group | £ 35 |
| Cardiff & Vale University Health Board | £70,000 |
| Hywel Dda University Health Board | £114,600 |
| Innovation Agency, Academic Health Science Network for the North West Coast | £11,509 |
| Manchester University NHS Foundation Trust on behalf of North West Genomics Laboratory Hub | £67,093 |
| NHS South East London Integrated Care Board | £80,000 |
| Nottingham University Hospitals NHS Trust | £140 |
| Royal Devon & Exeter NHS Foundation Trust on behalf of NHS South West Genomic Medicine Service Alliance | £64,261 |
| University Hospitals of Leicester NHS Trust | £70 |
Amgen partners with the NHS and other organisations for the benefit of patients and in a way that is true to the Industry Codes of Practice and Amgen’s policy. Amgen is committed to making public the scope of its partnerships in the UK and Ireland in order to increase transparency. This includes stating the transfers of value associated with all collaborative working projects each year.
| Kent Surrey & Sussex AHSN | £ 980 |
| The Innovation Agency AHSN | £ 56,509 |
| Northern Health Science Alliance Ltd | £ 10,000 |
| University Hospitals Bristol & Weston NHS FT | £ 10,354 |
| NHS Buckinghamshire CCG | £ 525 |
| University Hospitals Leicester NHS Trust | £ 13,996 |
| Cardiff & Vale University Health Board | £ 22,250 |
| Nottingham University Hospitals NHS Trust | £ 8,478.25 |
| North East & North Cumbria AHSN | £ 11,509 |
| South East London CCG | £ 120,000 |
Amgen partners with the NHS and other organisations for the benefit of patients and in a way that is true to the Industry Codes of Practice and Amgen’s policy. Amgen is committed to making public the scope of its partnerships in the UK and Ireland in order to increase transparency. This includes stating the transfers of value associated with all collaborative working projects each year.
| Kent Surrey & Sussex AHSN | £ 9,500.00 |
| The Innovation Agency AHSN | £ 242,500.00 |
| West Midlands AHSN | £ 40,000.00 |
| Northern Health Science Alliance Ltd | £ 18,000.00 |
| University Hospitals Bristol & Weston NHS FT | £ 17,574.50 |
| NHS Buckinghamshire CCG | £ 26,439.00 |
| University Hospitals Leicester NHS Trust | £ 17,838.50 |
| Northumbria Healthcare Foundation Trust | £ 30,300.50 |
| Cardiff & Vale University Health Board | £ 45,500.00 |
| Nottingham University Hospitals NHS Trust | £ 12,320.75 |
| North East & North Cumbria AHSN | £ 11,509.00 |
Amgen partners with patient advocacy groups for the benefit of patients and in a way that is true to the Industry Codes of Practice and Amgen's policy. Amgen is committed to making public the scope of its partnerships in the UK in order to increase transparency. This includes stating the amount of funding that Amgen provides each year.
For the purposes of transparency and clarity, the following declarations include grants, donations and sponsorships provided by Amgen Limited (UK), and grants, donations and sponsorships made by Amgen Inc. (USA) to patient advocacy organisations based in the UK.
In 2023, Amgen Ltd (UK) made the following payments:
Arthritis Action is the UK charity offering an integrated self-management approach, to help address the physical and mental health symptoms of living with arthritis.
In 2023, Amgen Ltd (UK) Provided a grant of £5,000 to enable the provision of support and information for patients impacted by arthritis, including support for young adults; raising awareness of the signs and symptoms of arthritis to increase understanding and diagnosis of the condition.
The UK’s leading bowel cancer charity, Bowel Cancer UK are determined to save lives and improve the quality of life of everyone affected by bowel cancer by championing early diagnosis and access to best treatment and care. They support and fund targeted research, provide expert information and support to patients and their families, educate the public and professionals about the disease, and campaign for early diagnosis and access to best treatment and care.
In 2023, Amgen Ltd (UK) provided a grant of £5,000 to support Bowel Cancer UK’s Healthcare Professional Events programme between September and October 2022. This included supporting their virtual National Colorectal Cancer Nurse Network Education Event in September and funding one bite-sized learning module.
HEART UK is the UK’s only cholesterol charity, providing support, information and influencing services for families and health professionals. Their vision is to prevent early disease and deaths from cholesterol and other blood fat (lipid) conditions in the UK. Their aim is for people to know and understand their cholesterol and other blood fat (lipid) levels and take appropriate action.
In 2023, Amgen Ltd (UK) provided sponsorship of £31,752 for membership of HEART UK’s CVD Collaborative Group and £12,500 for the LP(a) Taskforce; a proactive grant of £1,000 for their contributions to an Amgen internal educational event plus an honorarium of £1,165.65 for their attendance at that event. Sponsorship of £20,000 was paid for an exhibition stand, conference attendance and a symposia session at the Charity’s Annual Conference. In addition, honoraria and expenses were paid for their participation in an interview for website content (£345), for them to speak at the HealthPlus Care Conference (£432.05) and their attendance at and contribution to the development of a policy event at Holyrood (£3,352.61).
The ITP Support Association is a UK registered charity which aims to promote and improve the general welfare of patients, and the families of patients with immune (idiopathic) thrombocytopenic purpura (ITP).
In 2023, Amgen Ltd (UK) provided sponsorship of £13,000 in support of the Annual ITP Patients Convention, the aim of which is to provide awareness and education to help manage ITP and improve quality of life for those with ITP.
Leukaemia Care is the UK’s leading leukaemia charity. For over 50 years, they have been dedicated to ensuring that everyone affected receives the best possible diagnosis, information, advice, treatment and support.
In 2023, Amgen Ltd (UK) provided a grant of £5,000 to support the charity’s core activities, including improving the accessibility of their information sources; working on holistic and lifestyle support such as diet and nutrition; and expanding their hospital hubs that strengthen the clinical and community support provided to leukaemia patients.
Myeloma UK is the only organisation in the UK dealing exclusively with myeloma. The charity is dedicated to myeloma patients – making sure they get access to the right treatment at the right time. It strives to improve standards of treatment and care through research, education and raising awareness of myeloma.
In 2023, Amgen Ltd (UK) supported Myeloma UK with a grant of £20,000 to fund their Infoline and Ask the Nurse services, which provide vital access to information needed for patients and those around them to make sense of a myeloma diagnosis and to make informed decisions about treatment and care.
The National Rheumatoid Arthritis Society (NRAS), is the only patient-led organisation in the UK specialising in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Due to its targeted focus on RA and JIA, NRAS provides truly expert and wide-ranging services to support, educate and campaign for people living with these complex autoimmune conditions, their families and the health professionals who treat them.
In 2023, Amgen Ltd (UK) provided sponsorship of £12,000 towards corporate membership of NRAS.
The Royal Osteoporosis Society (ROS) is the UK’s largest national charity dedicated to improving bone health and beating osteoporosis.
In 2023, Amgen Limited (UK) provided sponsorship of £25,000 for a stand, conference and exhibitor passes and a 60 minute symposium slot at the Royal Osteoporosis Society 2023 Conference plus £1,794 for filming of the Amgen symposium at the conference.
In 2023, Amgen Inc. (USA) supported two international patient advocacy activities based in the UK. These are:
Roy Castle Lung Cancer Foundation is the leading UK lung cancer charity dedicated to helping everyone affected by the disease. They support everyone affected by lung cancer – from diagnosis, through treatment, living with the disease and end of life care.
In 2023, Amgen Inc. (USA) provided sponsorship of £30,000 for support of the Global Lung Cancer Coalition (GLCC) in 2024.
World Child Cancer is the leading international children’s charity dedicated to addressing the global inequality in childhood cancer care.
In 2023, Amgen Inc. (USA) provided sponsorship, with the first payment of $490,000, towards a collaboration project with World Child Cancer that will focus on improving early detection and access to treatment, strengthening pediatric oncology services for children with Burkitt lymphoma (BL) and delivering advocacy and sharing of learning for long-term impact. Amgen will provide funds towards the cost of running this project over 5 years (2023 - 2028).
All monies are shown in the currency paid. The reported figure to the Association of British Pharmaceutical Industry (ABPI) is in sterling (GBP).
2017 Onwards
Research and Development payments made to Healthcare Professionals and Healthcare Organisations are, from 2017 onwards, listed in aggregate form for the UK in the ABPI online database which can be found here: https://www.abpi.org.uk/our-ethics/disclosure-uk/
Amgen engages with members of the UK public including patients and journalists in line with Industry Codes of Practice and Amgen's policy requirements and is committed to make publicly available annually details of the fees provided for the contracted services. These services might include speaking at meetings, assistance with training, writing articles and/or publications, participating in advisory boards, advising on the design etc of clinical trials, participating in market research where such participation involves remuneration and/or travel.
For the purposes of transparency and clarity, the following declarations include fees provided by all Amgen entities to members of the public based in the UK, paid in 2023.
| Payments to Member(s) of the Public | |||
| NUMBER OF INDIVIDUALS | DESCRIPTION OF SUPPORT | CONTRACTED SERVICES FEE | CONTRACTED SERVICES OUT OF POCKET EXPENSES |
| 1 | Honoraria paid to participate in an Amgen organised meeting and funding to support attendance | 805.00 GBP | 23.40 GBP |
| 1 | Accommodation and travel support for participation at the International Bone Academy 2023 | 473.60 EUR | |
| Payments to Patients | |||
| NUMBER OF INDIVIDUALS | DESCRIPTION OF SUPPORT | CONTRACTED SERVICES FEE | CONTRACTED SERVICES OUT OF POCKET EXPENSES |
| 1 | Patient – Honoraria paid to speak at an Amgen organised meeting and funding to support attendance | 742.50 GBP | 247.50 GBP |
For the purposes of transparency and clarity, the following declarations include fees provided by all Amgen entities to members of the public based in the UK, paid in 2022.
| Payments to Members of the Public | ||
| NUMBER OF INDIVIDUALS | DESCRIPTION OF SUPPORT | CONTRACTED SERVICES FEE |
| 1 | Consultancy work for evidence generation and health economics activities | 1,207.00 GBP |
| Payments to Patients | ||
| NUMBER OF INDIVIDUALS | DESCRIPTION OF SUPPORT | CONTRACTED SERVICES FEE |
| 1 | A patient was engaged as a speaker at a Lipid Management meeting, held at The Scottish Parliament in November 2022 | 862.50 GBP |
| Payments to Journalist(s) | ||
| NUMBER OF INDIVIDUALS | DESCRIPTION OF SUPPORT | CONTRACTED SERVICES OUT OF POCKET EXPENSES |
| 1 | Event attendance at the 25th Anniversary of deCODE Genetics in Iceland | 1,157.27 GBP |